- Home
- MRCC vs ABOS Comparison
MRCC vs ABOS Comparison
Compare MRCC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ABOS
- Stock Information
- Founded
- MRCC 2011
- ABOS 1996
- Country
- MRCC United States
- ABOS United States
- Employees
- MRCC N/A
- ABOS N/A
- Industry
- MRCC Investment Managers
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- ABOS Health Care
- Exchange
- MRCC Nasdaq
- ABOS Nasdaq
- Market Cap
- MRCC 176.4M
- ABOS 72.7M
- IPO Year
- MRCC 2012
- ABOS 2021
- Fundamental
- Price
- MRCC $6.36
- ABOS $1.49
- Analyst Decision
- MRCC Hold
- ABOS Strong Buy
- Analyst Count
- MRCC 1
- ABOS 4
- Target Price
- MRCC $8.00
- ABOS $6.50
- AVG Volume (30 Days)
- MRCC 85.7K
- ABOS 623.5K
- Earning Date
- MRCC 08-06-2025
- ABOS 08-12-2025
- Dividend Yield
- MRCC 15.58%
- ABOS N/A
- EPS Growth
- MRCC 3301.50
- ABOS N/A
- EPS
- MRCC 0.32
- ABOS N/A
- Revenue
- MRCC $56,983,000.00
- ABOS N/A
- Revenue This Year
- MRCC N/A
- ABOS N/A
- Revenue Next Year
- MRCC N/A
- ABOS N/A
- P/E Ratio
- MRCC $19.76
- ABOS N/A
- Revenue Growth
- MRCC N/A
- ABOS N/A
- 52 Week Low
- MRCC $6.11
- ABOS $0.86
- 52 Week High
- MRCC $8.85
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- MRCC 49.55
- ABOS 58.51
- Support Level
- MRCC $6.32
- ABOS $1.12
- Resistance Level
- MRCC $6.50
- ABOS $1.27
- Average True Range (ATR)
- MRCC 0.16
- ABOS 0.06
- MACD
- MRCC 0.02
- ABOS 0.00
- Stochastic Oscillator
- MRCC 52.08
- ABOS 77.78
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.